We are live on ! Find out more

Arvinas

ARVN

Market cap $491M

7.51 USD

-0.08

1.05%

At close Updated Sep 28, 4:00 PM EDT

Pre-market

After hours

7.60

+0.09

1.2%

1 day

-1.05%

5 days

-10.27%

1 month

-18.19%

3 months

-9.41%

6 months

-26.23%

Year to date

-34.52%

1 year

-11.96%

5 years

-91.07%

10 years

-53.21%

About: Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Employees: 246

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 63.6%

Negative 0%

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish

Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.

Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish

Zacks Investment Research

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas Q2 Earnings Call Highlights

Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.

Arvinas Q2 Earnings Call Highlights

Zacks Investment Research

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

See News Rankings

Price charts implemented using Lightweight Charts™